EP3433285A1 - An improved process for the preparation of sugammadex - Google Patents
An improved process for the preparation of sugammadexInfo
- Publication number
- EP3433285A1 EP3433285A1 EP17720572.1A EP17720572A EP3433285A1 EP 3433285 A1 EP3433285 A1 EP 3433285A1 EP 17720572 A EP17720572 A EP 17720572A EP 3433285 A1 EP3433285 A1 EP 3433285A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sugammadex
- propionic acid
- process according
- mercapto propionic
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002370 Sugammadex Polymers 0.000 title claims abstract description 103
- WHRODDIHRRDWEW-VTHZAVIASA-N sugammadex Chemical compound O([C@@H]([C@@H]([C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]3[C@@H](CSCCC(O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC(O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC(O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC(O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC(O)=O)O[C@@H]([C@@H]([C@H]3O)O)O3)O[C@@H]2CSCCC(O)=O)O)[C@H](CSCCC(O)=O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]3[C@@H](CSCCC(O)=O)O1 WHRODDIHRRDWEW-VTHZAVIASA-N 0.000 title claims abstract description 101
- 229960002257 sugammadex Drugs 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims abstract description 75
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 53
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 29
- 239000003960 organic solvent Substances 0.000 claims abstract description 22
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 87
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 84
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 55
- 238000006243 chemical reaction Methods 0.000 claims description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000011541 reaction mixture Substances 0.000 claims description 31
- 239000007787 solid Substances 0.000 claims description 23
- 239000002585 base Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical group [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 17
- 229910052783 alkali metal Inorganic materials 0.000 claims description 17
- -1 alkali metal bicarbonates Chemical class 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 16
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 12
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 11
- 239000012296 anti-solvent Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000002140 halogenating effect Effects 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 5
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910003002 lithium salt Inorganic materials 0.000 claims description 4
- 159000000002 lithium salts Chemical class 0.000 claims description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 239000011630 iodine Chemical group 0.000 claims description 3
- 229910052740 iodine Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 claims description 2
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 44
- 239000012535 impurity Substances 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 230000035484 reaction time Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000005660 chlorination reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 238000005658 halogenation reaction Methods 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229920000856 Amylose Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940041644 bridion Drugs 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000026030 halogenation Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KMGKABOMYQLLDJ-VKHHSAQNSA-F sugammadex sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O([C@@H]([C@@H]([C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CSCCC([O-])=O)O[C@@H]([C@@H]([C@H]3O)O)O3)O[C@@H]2CSCCC([O-])=O)O)[C@H](CSCCC([O-])=O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]3[C@@H](CSCCC([O-])=O)O1 KMGKABOMYQLLDJ-VKHHSAQNSA-F 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000000842 neuromuscular blocking agent Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- OWWLUIWOFHMHOQ-XGHATYIMSA-N Pipecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)N2CC[N+](C)(C)CC2)CC[N+](C)(C)CC1 OWWLUIWOFHMHOQ-XGHATYIMSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001260 pipecuronium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 description 1
- 229960000491 rocuronium Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
- 229960003819 vecuronium Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Definitions
- the present application provides an improved process for the preparation of sugammadex. More particularly, the application relates to a reaction of a salt of 3- mercapto propionic acid with to obtain
- sugammadex wherein said salt is preferably selected from the group comprising of di sodium salt of 3-mercapto propionic acid, di potassium salt of 3-mercapto propionic acid and di lithium salt of 3-mercapto propionic acid.
- This application also relates to the use of isolated crystalline compound di alkali metal salt of 3- mercapto propionic acid for the preparation of sugammadex, which improves overall purity and/or reaction time of sugammadex.
- the present application provides an improved industrially viable process, which is efficient, less time consuming, reproducible and involves less toxic reagents.
- Sugammadex is marketed as Bridion ® and structurally known as compound of formula I, whereas formula I shows the sodium salt of sugammadex. It is an octa substituted ⁇ -cyclodextrin derivative with a lipophilic core and a hydrophilic periphery.
- cyclodextrins contains a cyclic oligosaccharides composed of a-(l,4) linked glucopyranose subunits.
- an a (alpha)-cyclodextrin is a 6- membered ring molecule
- a ⁇ (beta)-cyclodextrin is a 7-membered ring molecule
- a ⁇ (gamma)-cyclodextrin is a 8-membered ring molecule.
- Cyclodextrins are useful molecular chelating agents. They possess a cage-like supramolecular structure. As a result of molecular complexation phenomena CDs are widely used in many industrial products, technologies and analytical methods.
- Sugammadex contains substituted ⁇ -cyclodextrin with eight recurring amylose units each with five asymmetric carbon atoms, in total forty asymmetric carbon atoms for the whole molecule. The original configuration of all asymmetric carbon atoms is retained during the synthetic manufacturing process.
- sugammadex is a potent and effective agent for the reversal of neuromuscular blockade induced by the steroidal neuromuscular blocking agents (NMBA) such as rocuronium, vecuronium and pipecuronium.
- NMBA steroidal neuromuscular blocking agents
- Sugammadex was at least disclosed as early as the publication of WO2001/40316A1 (hereinafter referred as WO'316).
- This publication discloses'a process for preparation of sugammadex which involves iodination of dry ⁇ - cyclodextrin to obtain 6-per-deoxy-6-per-iodo-Y-cyclodextrin as a yellow solid.
- the 6-per-deoxy-6-per-iodo-Y-cyclodextrin was dissolved in dimethylformamide and added slowly to a mixture of 3-mercaptopropionic acid and sodium hydride in dry dimethylformamide.
- the obtained mixture was heated at 70°C for 12 Hours.
- the mixture was cooled and water was added to the mixture.
- the volume of the mixture was reduced under vacuum by evaporation followed by addition of ethanol to precipitate sugammadex.
- WO2012/025937A1 discloses the preparation of sugammadex by chlorination of ⁇ -cyclodextrin with phosphorous pentachloride in dimethylformamide, after completion of the chlorination the solvent was removed to obtain a viscous residue.
- the viscous residue was diluted with water followed by adjusting the pH 8 with 5M sodium hydroxide to obtain slurry, it was then filtered, washed with water and dried to give 6-per-deoxy-6-per-chloro-7- cyclodextrin.
- the chlorinated ⁇ -cyclodextrin was dissolved in dimethylformamide and added slowly to a mixture of 3-mercaptopropionic acid and sodium hydride in dimethylformamide. The obtained mixture was heated at 70-75°C for 12 Hours. The dimethylformamide was partially removed then diluted with ethanol to obtain a precipitate. The precipitate is stirred for one hour and filtered to obtain crude sugammadex. The crude sugammadex was purified over silica gel and Sephadex G-25* column using water as eluent.
- mercaptopropionic acid is also high (about 12 Hours).
- WO2014/125501 Al discloses the preparation of sugammadex by chlorination of ⁇ -cyclodextrin with phosphorous pentachloride in dimethylformamide. After completion of the chlorination, the mixture was quenched with water. The obtained mixture was hydrolyzed with aqueous sodium hydroxide solution, filtered, washed repeatedly with water and dried to give 6-per- deoxy-6-per-chloro-7-cyclodextrin.
- the chlorinated ⁇ -cyclodextrin was added slowly to a mixture of 3-mercaptopropionic acid and sodium methoxide in methanol and dimethylformamide, then heated to 75-80°C and maintained at 75- 80°C for 12 to 14 Hours to give crude sugammadex.
- the crude sugammadex was purified by treating it with activated carbon in a mixture of water and methanol.
- mercaptopropionic acid is also high (about 12 to 14 Hours).
- CNl 04844732A2 discloses an alternative process for the preparation of sugammadex by reacting with thiourea in dimethylformamide at 90°C for 12 Hours. After completion of the reaction, the solvent was partially evaporated followed by addition of ethanol to obtain a precipitate. The resulting solid precipitate was treated with aqueous sodium hydroxide solution followed by adjusting the pH 2 with hydrochloric acid. The ethanol was added to the mixture to obtain a solid residue, which was recrystallized in water to obtain 6-per-deoxy-6-per-mercapto-7-cyclodextrin.
- the 6-per-deoxy-6-per-mercapto-y-cyc[odextrin was reacted with acrylic acid in water under UV light exposure at 20°C for 6 Hours.
- the pH of the solution was adjusted to 9 with aqueous sodium hydroxide solution followed by filtering the solution from nanofiltration membrane to obtain sugammadex.
- the application provides an improved process for the preparation of sugammadex, said process comprises the following steps;
- X is chlorine, bromine or iodine
- a salt of 3-mercapto propionic acid selected from the group comprising of di sodium salt of 3-mercapto propionic acid, di potassium salt of 3-mercapto propionic acid and di lithium salt of 3-mercapto propionic acid, preferably with the di sodium salt of 3-mercapto propionic acid of formula III,
- sugammadex salt preferably the sodium salt of formula I.
- the application provides an improved process for the preparation and isolation of a salt of 3-mercapto propionic acid, selected from the group comprising of di sodium salt of 3-mercapto propionic acid, di potassium salt of 3-mercapto propionic acid and di lithium salt of 3-mercapto propionic acid, preferably the di sodium salt of 3-mercapto propionic acid of formula III,
- said process comprises the following steps,
- alkali metal hydroxide base is selected from a group comprising of sodium hydroxide (NaOH), lithium hydroxide (LiOH) and potassium hydroxide (KOH), preferably with sodium hydroxide (NaOH), b) isolating the di alkali metal salt of 3-mercapto propionic acid, preferably the di sodium salt of 3-mercapto propionic acid,
- the application provides crystalline compound of a di alkali metal salt of 3-mercapto propionic acid, preferably the di sodium salt of 3- mercapto propionic acid of formula III,
- FIG. 1 is an illustration of a PXRD pattern of crystalline form of di sodium salt of 3-mercapto propionic acid.
- alkali metal, alkali metal hydroxide and alkali metal salt refer to lithium (Li), sodium (Na) and/or potassium (K), its hydroxides and salts, respectively.
- polymorphism refers to the ability of a substance to exist as two or more crystalline phases that have different spatial arrangements and/or conformations of molecules in their crystal lattices.
- polymorphs refer to different crystalline forms of the same pure substance in which the molecules have different spatial arrangements of the molecules, atoms, and/or ions forming the crystal.
- Different polymorphs may have different physical properties such as melting points, solubilities, X-ray diffraction patterns, etc.
- anti-solvent refers to a liquid that, when combined with a solution of sugammadex, reduces solubility of the sugammadex in the solution, causing crystallization or precipitation in some instances spontaneously, and in other instances with additional steps, such as seeding, cooling, scratching, and/or concentrating.
- the application provides an improved process for the preparation of sugammadex by reacting 6-per-deoxy-6-per-halo-7-cyclodextrin (halogenated- ⁇ - cyclodextrin) with di alkali metal salt of 3-mercapto propionic acid in suitable organic solvent.
- the sugammadex may be further purified to get desired purity of sugammadex.
- the improved process of the present application is advantageous over the prior art procedures at least because the reaction of halogenated-y-cyclodextrin with isolated di alkali metal salt of 3-mercapto propionic acid is very selective, which in turn avoids the formation of unwanted impurities.
- the halogen is chlorine and the alkali metal salt is of sodium.
- the prior art procedures disclose the preparation of a solution of 3-mercapto propionic acid in the presence of suitable base in a suitable solvent. The prepared solution containing large quantity of base, which is further mixed with 6-per-deoxy-6-per-halo-7-cyclodextrin to afford sugammadex. It has been observed that the presence of excessive base during the substitution reaction of 6-per-deoxy-6-per-halo-y-cyclodextrin with 3- mercapto propionic acid produces unwanted impurities, which are very difficult to remove from the reaction mixture.
- the process of present application involves the preparation and isolation of di alkali metal salt of 3-mercapto propionic acid preferably the di sodium salt of 3- mercapto propionic acid as solid prior to its reaction with 6-per-deoxy-6-per-halo- ⁇ -cyclodextrin.
- di sodium salt of 3-mercapto propionic acid for the reaction reduces the excessive content of base during the substitution reaction of 6-per-deoxy-6-per-halo-y-cyclodextrin. It has been observed that impurities like Impurity I and Impurity II (Table A) are very susceptible to the quality and the choice of the base.
- Impurity I is directly correlated to the strength of the base used, while Impurity II is strictly correlated to the presence of sodium methoxide in the reaction medium.
- the present process effectively reduces the presence of Impurity ⁇ (Table A) in the final sugammadex, which is currently present in the commercially available samples (Bridion) at a content of 4 area-% HPLC (High Performance Liquid Chromatography).
- the content of Impurity I is not detected in the samples of sugammadex prepared according to process of the present application, it is mainly due to isolation of di sodium salt of 3-mercapto propionic acid as solid.
- the isolation of solid intermediate significantly reduces the content of base during its reaction with 6- hence the formation of Impurity I is greatly reduced.
- the below comparative data discloses the content of three different impurities in the prepared sugammadex.
- the process of the present application is performed under oxygen free condition to avoid the formation of oxidation sensitive impurities.
- the process of the present application is economical and effective for large scale production of sugammadex as the reaction time of 6-per-deoxy-6-per-halo-7- cyclodextrin with 3-mercapto propionic acid is greatly reduced as compared to the prior art procedures. Further, it is observed that reaction mixture of the said substitution reaction of the present application is not viscous as compared to the prior art procedures. Due to low viscosity the handling and stirring of the reaction mixture is not tedious, which is useful for large scale production of sugammadex.
- sugammadex is preferably prepared by reacting 6-per-deoxy-6-per-chloro-Y-cyclodextrin with isolated solid di sodium salt of 3-mercaptopropionic acid in suitable organic solvent.
- Said organic solvent can be selected form ethyl acetate, acetonitrile, propionitrile, tetrahydrofuran, dimethylformamide, dimethylacetamide, N-methyl-2- pyrrolidone, dimethyl sulfoxide or mixtures thereof. More preferably the organic solvent can be selected from dimemylformamide or dimethyl sulfoxide and most preferably the organic solvent is dimethyl sulfoxide.
- the reaction can be carried out at any suitable temperature, but preferably from 40°C to 90°C or at the reflux temperature of the solvent.
- the reaction can be completed in about 2 to 6 Hours, more preferably in about 3 to 5 Hours.
- dimethyl sulfoxide as reaction solvent in combination with the use of isolated solid di sodium salt of 3-mercaptopropionic acid, which accelerates the reaction leading to high substitutions in short reaction times and results in full substitutions of all eight halogenated positions of 6-per- deoxy-6-per-cWoro-7-cyclodextrin with 3-mercaptopropionic acid, more than 99% conversion is achieved by stirring the reaction mixture at 70°C for about 2 to 6 Hours.
- the completion of the reaction can be monitored by any suitable analytical technique.
- sugammadex may be isolated by any known methods which may include but not limited to cooling crystallization, anti- solvent addition, removal of solvent by evaporation, distillation, filtration of precipitated solid and the like; or any combinations of these methods.
- the isolated sugammadex may optionally be purified to achieve desired purity and quality by techniques known in art like column chromatography, fractional distillation, acid base treatment, slurrying or recrystallization.
- the sugammadex can be purified by dissolving it in a suitable solvent like water followed by mixing with an anti solvent to isolate sugammadex. It is also advantageous to treat the mixture with activated carbon prior to addition of an anti solvent.
- the anti solvent can be selected from alcoholic solvent such as methanol, ethanol, isopropyl alcohol, acetone, tetrahydrofuran, dimethylformamide and dimethyl sulfoxide or mixtures thereof.
- the purified sugammadex may be optionally washed with suitable solvent and dried under suitable drying conditions.
- the drying may be suitably carried out using any of an air tray dryer, vacuum tray dryer, fluidized bed dryer, spin flash dryer, flash dryer, and the like.
- the drying may be carried out at any suitable temperatures and under atmospheric pressure or above, or under reduced pressures.
- the present application provides the preparation and isolation of di alkali metal salt of 3-mercapto propionic acid.
- the di alkali metal salt of 3- mercapto propionic acid may be prepared by reacting 3-mercapto propionic acid with suitable base preferably an alkali metal hydroxide base in suitable organic solvent and isolating the di alkali metal salt of 3-mercapto propionic acid as solid.
- the alkali metal hydroxide base can be selected from lithium hydroxide, potassium hydroxide, sodium hydroxide or mixtures thereof.
- the most preferred alkali metal hydroxide base is sodium hydroxide and di alkali metal salt of 3- mercapto propionic acid is di sodium salt of 3-mercapto propionic acid.
- the preferred organic solvent can be selected from the list of organic solvent as discussed above. The most preferred organic solvent is tetrahydrofuran.
- the application provides novel crystalline compound of di sodium salt of 3-mercapto propionic acid of formula III,
- the crystalline di sodium salt of 3-mercapto propionic acid of formula ⁇ shows on X-ray diffraction peak at an angle of refraction 2 theta ( ⁇ ), of 9.08, 22.14,
- the 6-per-deoxy-6-per-halo-Y-cyclodextrin of compound, used as starting material for the preparation of sugammadex of the present application, can be prepared by any suitable methods known in the prior arts such as methods disclosed in WO2001/040316A1, WO2012/025937A1 and WO2014/125501A1.
- halogenating reagent can be selected from iodine, N-iodosuccinimide, oxalyl chloride, oxalyl bromide, thionyl chloride, thionyl bromide, phosphoryl chloride or phosphoryl bromide; more preferably the halogenating reagent can be selected from oxalyl chloride or thionyl chloride.
- the organic solvent for the halogenation reaction can be selected from the list of organic solvent as discussed above. The most preferred organic solvent is dimethylformamide.
- the halogenation of ⁇ -cyclodextrin produces a complex with the halogenating reagent and solvent, which is further hydrolysed with a suitable base in a suitable solvent/anti-solvent mixture to isolate 6-per-deoxy-6-per-halo-Y-cyclodextrin.
- the anti-solvent is a mixture of alcoholic solvent and water.
- the solvent of solventanti-solvent pair can be selected from the list of organic solvents as discussed above.
- the alcoholic component of the anti-solvent can be selected from CI -4 alcohol such as methanol, ethanol, propanol, isopropyl alcohol, n-butanol, iso-butanol, tert-butanol or mixtures thereof.
- the suitable base can be selected from alkali metal hydroxide such as sodium hydroxide, lithium hydroxide, potassium hydroxide and the like; alkali metal carbonate and /or alkali metal bicarbonate such as potassium carbonate, lithium carbonate, sodium carbonate, potassium bicarbonate, lithium bicarbonate, sodium bicarbonate and the like.
- alkali metal hydroxide such as sodium hydroxide, lithium hydroxide, potassium hydroxide and the like
- alkali metal carbonate and /or alkali metal bicarbonate such as potassium carbonate, lithium carbonate, sodium carbonate, potassium bicarbonate, lithium bicarbonate, sodium bicarbonate and the like.
- the halogenation of ⁇ -cyclodextrin is performed by reacting it with a suspension of oxalyl chloride or thionyl chloride in dimethylformamide under anhydrous condition at about -5°C to 15°C, more preferably at about 0°C to 10°C.
- the suspension of oxalyl chloride or thionyl chloride can be prepared by slow addition to dimethylformamide at about -S°C to 15°C.
- the obtained suspension is further heated and mixed with ⁇ -cyclodextrin.
- ⁇ -cyclodextrin with the suspension of oxalyl chloride or thionyl chloride can be achieved by addition of ⁇ -cyclodextrin to the suspension or vice-versa, in both cases slow addition is preferred.
- the obtained mixture may be stirred at a temperature of about 40°C to 90°C, more preferably at about 60°C to 80°C for a period of about 5 to 25 Hours, preferably for about 10 to 20 Hours.
- the solution After completion of the reaction the solution is cooled and an alcoholic solvent, preferably methanol, is added then stirred for a period of time.
- the obtained solution is slowly added to an aqueous solution of base and methanol and then stirred for an appropriate time preferably for about 1 to 6 Hours, more preferably for about 1 to 4 Hours.
- the 6-per-deoxy-6-per-chloro-y-cyclodextrin can be isolated from the reaction mixture by suitable techniques such as filtration, decantation or centrifugation and the like.
- the isolated 6-per-deoxy-6-per-chloro- ⁇ -cyclodextrin may optionally be washed with aqueous methanol and if required, may optionally be further purified to obtain the desired purity of 6-per-deoxy-6- per-chloro-Y-cyclodextrin.
- One embodiment of the process for preparing sugammadex comprises the following steps;
- step 6) dissolving sugammadex of step 5) in water, 7) optionally, adding activated carbon,
- 3-Mercapto propionic acid (1.95 mL, 10 eq.) was dissolved in dry dimethylformamide (72 mL) under nitrogen at room temperature. To this solution was added in three portions sodium hydride (1.97 g, 22 eq., 60% dispersion in mineral oil) and the mixture was stirred for another 30 minutes. To this mixture was then added drop wise a solution of 6-per-deoxy-6-per-iodo-Y-cyclodextrin (5 g, 2.24 mmol) in dry dimethylformamide (72 mL). After addition, the reaction mixture was heated at 70°C for 12 Hours. After cooling, water (16 mL) was added to the mixture and the volume was reduced to 64 mL in vacuo.
- the crude product (11.4 g) was dissolved in water (17 mL, 1.5 vol.) and methanol (17 mL, 1.5 vol.), treated with activated carbon (2.28 g, 20% w/w) and was filtered, washed the carbon cake with purified water (5 mL, 1 vol.)- The filtrate was heated to 50-55°C and slowly methanol (130 mL) was added at the same temperature in 1 Hour. The resulted suspension was cooled to 20-25°C and stirred for 2 Hours at the same temperature. The resulted solid was filtered, washed with methanol (10 mL, 2 vol.) and dried under vacuum at 60-65°C for 14 Hours to obtain 4.9 g of white solid with a purity of 88.5% area-% HPLC.
- reaction mass-1 Dimethylformamide (900 mL) was added to a reaction flask. The reaction mass was cooled to 0-10°C and oxalyl chloride (distilled) (318 mL, 32eq.) added by maintaining temperature at 0-10°C. After complete addition, the reaction mass was heated to 60-65°C. The ⁇ -cyclodextrin (150 gm dissolved in 300 mL dimemylfonnamide) was added slowly into the reaction mass by maintaining the temperature at 60-65°C. After complete ⁇ -cyclodextrin addition, reaction mass was stirred at 60-65°C for 15 Hours. Then the reaction mass was cooled to 20-25°C and methanol (1200 mL) was added and the reaction mass was stirred for another 5-10 minutes at 20-30°C.
- oxalyl chloride distilled
- reaction mass-2 Water (2700 mL) and potassium bicarbonate (463 gm) were mixed and stirred for 10-15 minutes at 20-30°C. Methanol (1500 mL) was added to the stirred solution and again stirred for 20-30 minutes at 20-30°C.
- reaction mass-1 was added slowly to the reaction mass-2 at 20-30°C. Addition was completed in 2-3 Hours at 20-30°C. The reaction mass was further stirred for 5-6 Hours at 20-30°C. After completion of the reaction, the reaction mass was filtered and the obtained solid was washed with methanol: water (1:1) (two times with 750 mL). Then the solid was washed with methanol (750 mL) and dried for 30 minutes to obtain the crude compound 160 g.
- the wet solid was stirred in tetrahydrofuran (500 ml) and dimethylformamide (250 ml) at 20 to 25°C for 1 hour under nitrogen atmosphere.
- the suspension was filtered, washed with tetrahydrofuran : dimethylformamide (1:1) (200 ml) and dried under vacuum at 45-50°C for 15 Hours to give 72 g of disodium salt of 3- mercaptopropionic acid.
- the obtained product had a purity of 97 area-% HPLC.
- Example 4A Dimethyl sulfoxide (500 ml) was de-oxygenated with three cycles of nitrogen, vacuum and nitrogen at 20-30°C.
- the di-sodium salt of 3- mercaptopropionic acid (46 g, 0.306 moles) was added and the reaction mass was again de-oxygenated with two cycles of nitrogen and vacuum at 20-25°C.
- the 6- per-deoxy-6-per-chloro-Y-cyclodextrin 25 g, 0.017 moles
- Example 4B The crude sugammadex (43 g) was added to 180 ml of water at 20- 30°C and the mixture was stirred for 10-20 minutes at the same temperature to get a clear solution.
- Dimethyl sulfoxide (205 ml) was slowly added to the reaction mixture at 25-35°C and the reaction mixture was then stirred at 20-30°C for 1 hour. Further Dimethyl sulfoxide (65 mL) was added and the reaction mixture stirred for 1 hour at same temperature. The resultant solid was filtered, washed with 10% aqueous dimethyl sulfoxide (100 ml), ethanol (300 ml) and dried at 50- 55°C for 12 hour to give 28.10 g sugammadex.
- Example 4C The sugammadex (28 g) obtained from example 4B was dissolved in water (380 ml) and methanol (380 ml) at 20-30°C. To this solution activated carbon (2.8 g, 10% w/w) was added and stirred for 2 Hours at 20-30°C. The reaction mixture was filtered through celite and washed with methanol: water (1:1) (38 ml). The filtered solution was heated to 45-50°C and methanol (2400 ml) was slowly added at the same temperature. The reaction mixture was then slowly cooled to 20-30°C and stirred at the same temperature for 1 Hour.
- Dimethyl sulfoxide 200 ml was de-oxygenated with nitrogen, vacuum and nitrogen at 20-30°C.
- the di-sodium salt of 3 -mercaptopropionic acid (16.6 g, 0.1107 moles) was added and the reaction mass was again de-oxygenated with nitrogen and vacuum at 20-25°C.
- the 6-per-deoxy-6-per-chloro-y-cyclodextrin (10 g, 0.0069 moles ) was dissolved in dimethyl sulfoxide (SO ml) under nitrogen at 20-30°C and added to the reaction mass at 20-25°C. Then the reaction mixture was de-oxygenated with vacuum and nitrogen at 20-30°C.
- the reaction mixture was heated to 70-75°C and stirred for 4-5 hour at 70-75°C.
- the reaction mass was cooled to 20-30°C and diluted with water (250 ml) at 20-35°C.
- Dimethyl sulfoxide (2000 ml) was de-oxygenated with nitrogen, vacuum and nitrogen at 20-30°C.
- the di-sodium salt of 3- mercaptopropionic acid (166.2 g, 1.107 moles) was added and the reaction mass was again de-oxygenated with nitrogen and vacuum at 20-25°C.
- the 6-per-deoxy-6-per-chloro-y-cyclodextrin (100 g, 0.069 moles ) was dissolved, in dimethyl sulfoxide (500 ml) under nitrogen at 20-30°C and added to the reaction mass at 20-25°C. Then the reaction mixture was de-oxygenated with vacuum and nitrogen at 20-30°C.
- the reaction mixture was heated to 70-75°C and stirred for 4-6 hour at 70-75°C.
- the reaction mass was cooled to 20-30°C and diluted with water (2500 ml) at 20-35°C.
- dimethyl sulfoxide (1800 ml) to the reaction mass in two lots at 20-35°C and stirred for overnight at 20-30°C, then filtered the mass under nitrogen, washed with 20% aqueous dimethyl sulfoxide (400 ml), suck dried under vacuum 1-2 hours to give 220gm Sugammadex.
- the obtained Sugammadex was dissolved in 800 ml of water.
- Dimethyl sulfoxide (1600 ml) was slowly added to the reaction mixture at 25-35°C in two lots and the mass was stirred for 3 hour at 20-30°C.
- the mass was filtered and washed with 20% aqueous dimethyl sulfoxide (400 ml), methanol (500ml) and suck dried under nitrogen for 1 hour to give 100 g wet Sugammadex.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20175964.4A EP3733717A3 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
SI201730346T SI3433285T1 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201611009993 | 2016-03-22 | ||
PCT/IB2017/051594 WO2017163165A1 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20175964.4A Division EP3733717A3 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3433285A1 true EP3433285A1 (en) | 2019-01-30 |
EP3433285B1 EP3433285B1 (en) | 2020-06-03 |
Family
ID=58645335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17720572.1A Active EP3433285B1 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
EP20175964.4A Withdrawn EP3733717A3 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20175964.4A Withdrawn EP3733717A3 (en) | 2016-03-22 | 2017-03-20 | An improved process for the preparation of sugammadex |
Country Status (9)
Country | Link |
---|---|
US (1) | US10577433B2 (en) |
EP (2) | EP3433285B1 (en) |
JP (1) | JP6829304B2 (en) |
KR (1) | KR20180127428A (en) |
CN (1) | CN108779186B (en) |
AU (1) | AU2017236669B2 (en) |
ES (1) | ES2810980T3 (en) |
SI (1) | SI3433285T1 (en) |
WO (1) | WO2017163165A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380554B1 (en) | 2015-11-25 | 2020-06-10 | Fresenius Kabi iPSUM S.r.l. | Crystalline forms of per-chloro-gamma-cyclodextrines |
EP3380530B1 (en) | 2015-11-25 | 2020-10-07 | Fresenius Kabi iPSUM S.r.l. | An improved process for the preparation of sugammadex and its intermediates |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20220705T1 (en) | 2016-06-23 | 2022-07-22 | Synthon B.V. | Process for making sugammadex |
US10385142B2 (en) * | 2017-01-23 | 2019-08-20 | Scinopharm Taiwan, Ltd. | Method for preparing sugammadex sodium |
US10336835B2 (en) * | 2017-08-23 | 2019-07-02 | Formosa Laboratories, Inc. | Polymorphs of sugammadex and process for preparation of sugammadex |
CN107892727B (en) * | 2017-11-27 | 2019-12-24 | 合肥博思科创医药科技有限公司 | Method for purifying sugammadex sodium |
WO2019102009A1 (en) | 2017-11-27 | 2019-05-31 | Medichem, S.A. | Process for the synthesis of a cyclodextrin derivative |
HRP20220728T1 (en) | 2018-04-06 | 2022-08-05 | Synthon B.V. | Purification of sugammadex |
CA3102090A1 (en) * | 2018-06-07 | 2019-12-12 | Merck Sharp & Dohme Corp. | Processes for the preparation of sugammadex |
CN110655594B (en) * | 2018-06-29 | 2021-04-30 | 江苏海悦康医药科技有限公司 | Preparation method of monohydroxy sugammadex sodium |
WO2020013759A1 (en) * | 2018-07-12 | 2020-01-16 | Scinopharm Taiwan Ltd. | Method for preparing sugammadex sodium |
CN109053933B (en) * | 2018-08-01 | 2020-10-23 | 合肥博思科创医药科技有限公司 | Preparation method of amorphous sugammadex sodium |
WO2020058987A1 (en) | 2018-09-20 | 2020-03-26 | Natco Pharma Limited | An improved process for the preparation of sugammadex sodium and its novel polymorphic form |
JP2022501489A (en) * | 2018-09-27 | 2022-01-06 | ヴェルテンシュタイン・バイオファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | New crystal type of Sugamadex |
CN109593143B (en) * | 2018-12-29 | 2021-02-09 | 博瑞生物医药(苏州)股份有限公司 | Purification method for preparing intermediate from sugammadex sodium |
CN109824800A (en) * | 2018-12-29 | 2019-05-31 | 鼎元(天津)生物医药科技有限公司 | A kind of preparation method of the easypro more glucose sodium of selectivity flesh pine antagonistic |
EP3753946A1 (en) | 2019-06-18 | 2020-12-23 | Fresenius Kabi iPSUM S.r.l. | Improved process for the preparation of high purity glucagon |
US11324692B2 (en) | 2019-07-03 | 2022-05-10 | Galenicum Health S.L.U. | Method to prepare pharmaceutical compositions of suggamadex |
US20230167203A1 (en) | 2020-02-28 | 2023-06-01 | Medichem, S.A. | Method for drying sugammadex |
CN113456598B (en) * | 2020-03-31 | 2024-04-02 | 鲁南制药集团股份有限公司 | Sodium gluconate freeze-dried powder injection and preparation method thereof |
US11097023B1 (en) | 2020-07-02 | 2021-08-24 | Par Pharmaceutical, Inc. | Pre-filled syringe containing sugammadex |
ES2949710T1 (en) | 2020-07-03 | 2023-10-02 | Galenicum Health S L U | Method for preparing pharmaceutical compositions |
CN112279938A (en) * | 2020-10-26 | 2021-01-29 | 江苏阿尔法药业有限公司 | Preparation method of sugammadex drug intermediate |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
CN101864003B (en) | 2010-06-11 | 2012-05-02 | 漆又毛 | Synthesis method of 6-deoxy thioether amino acid cyclodextrin derivative |
WO2012025937A1 (en) * | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | Improved process for preparation of sugammadex |
WO2014125501A1 (en) * | 2013-02-14 | 2014-08-21 | Neuland Laboratories Limited | An improved process for preparation of sugammadex sodium |
CN105273095A (en) * | 2014-05-28 | 2016-01-27 | 四川海思科制药有限公司 | Preparation method for sugammadex and intermediates thereof |
CN104844732B (en) | 2015-03-27 | 2017-05-03 | 山东滨州智源生物科技有限公司 | Preparation method for sugammadex sodium |
CN107849157A (en) | 2015-05-29 | 2018-03-27 | 拉克什米·普拉萨德·阿拉帕斯 | The method for preparing relax more glucose and its intermediate |
CN106749771A (en) * | 2015-11-23 | 2017-05-31 | 成都渊源生物科技有限公司 | A kind of easypro more glucose sodium preparation method of high-purity |
CN108291057B (en) | 2015-11-25 | 2021-07-13 | 费森尤斯卡比依普莎姆有限责任公司 | Crystalline forms of perchloro-gamma-cyclodextrin |
ES2829236T3 (en) | 2015-11-25 | 2021-05-31 | Fresenius Kabi Ipsum S R L | Improved procedure for the preparation of sugammadex and its intermediates |
-
2017
- 2017-03-20 US US16/087,065 patent/US10577433B2/en active Active
- 2017-03-20 WO PCT/IB2017/051594 patent/WO2017163165A1/en active Application Filing
- 2017-03-20 SI SI201730346T patent/SI3433285T1/en unknown
- 2017-03-20 CN CN201780018634.1A patent/CN108779186B/en active Active
- 2017-03-20 EP EP17720572.1A patent/EP3433285B1/en active Active
- 2017-03-20 AU AU2017236669A patent/AU2017236669B2/en active Active
- 2017-03-20 ES ES17720572T patent/ES2810980T3/en active Active
- 2017-03-20 JP JP2019501771A patent/JP6829304B2/en active Active
- 2017-03-20 EP EP20175964.4A patent/EP3733717A3/en not_active Withdrawn
- 2017-03-20 KR KR1020187030271A patent/KR20180127428A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380554B1 (en) | 2015-11-25 | 2020-06-10 | Fresenius Kabi iPSUM S.r.l. | Crystalline forms of per-chloro-gamma-cyclodextrines |
EP3380530B1 (en) | 2015-11-25 | 2020-10-07 | Fresenius Kabi iPSUM S.r.l. | An improved process for the preparation of sugammadex and its intermediates |
Also Published As
Publication number | Publication date |
---|---|
US20190284308A1 (en) | 2019-09-19 |
KR20180127428A (en) | 2018-11-28 |
SI3433285T1 (en) | 2020-10-30 |
AU2017236669B2 (en) | 2021-02-18 |
EP3733717A2 (en) | 2020-11-04 |
CN108779186B (en) | 2021-07-13 |
AU2017236669A1 (en) | 2018-09-27 |
EP3433285B1 (en) | 2020-06-03 |
CN108779186A (en) | 2018-11-09 |
EP3733717A3 (en) | 2020-12-30 |
US10577433B2 (en) | 2020-03-03 |
JP2019510128A (en) | 2019-04-11 |
WO2017163165A1 (en) | 2017-09-28 |
JP6829304B2 (en) | 2021-02-10 |
ES2810980T3 (en) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017236669B2 (en) | An improved process for the preparation of sugammadex | |
AU2016359420B2 (en) | An improved process for the preparation of sugammadex and its intermediates | |
EP3380554B1 (en) | Crystalline forms of per-chloro-gamma-cyclodextrines | |
EP3474865A2 (en) | Process for making sugammadex | |
KR20100015633A (en) | Process for the preparation of tauroursodeoxycholic acid | |
JP6670744B2 (en) | Polymorphic forms of sodium hyodeoxycholate (NaHDC) and methods for their preparation | |
KR20230037582A (en) | Diosmin manufacturing method | |
WO2020201930A1 (en) | An improved process for preparation of sugammadex acid and sugammadex sodium | |
US11447513B2 (en) | Purification process of ferric carboxymaltose | |
JPH06239903A (en) | Cyclodextrin derivative and its production | |
CN110615858A (en) | Preparation method of sugammadex intermediate | |
JPH0753605A (en) | Production of cyclodextrin derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FRESENIUS KABI IPSUM S.R.L. |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: FRESENIUS KABI IPSUM S.R.L. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190910 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200316 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40005673 Country of ref document: HK |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1276937 Country of ref document: AT Kind code of ref document: T Effective date: 20200615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017017662 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200904 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200903 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200903 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1276937 Country of ref document: AT Kind code of ref document: T Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201006 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201003 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017017662 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2810980 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210310 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
26N | No opposition filed |
Effective date: 20210304 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210320 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230306 Year of fee payment: 7 Ref country code: FR Payment date: 20230302 Year of fee payment: 7 Ref country code: CZ Payment date: 20230221 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20230217 Year of fee payment: 7 Ref country code: IT Payment date: 20230222 Year of fee payment: 7 Ref country code: GB Payment date: 20230302 Year of fee payment: 7 Ref country code: DE Payment date: 20230213 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200603 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230307 Year of fee payment: 7 Ref country code: MT Payment date: 20230214 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170320 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230404 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240202 Year of fee payment: 8 Ref country code: IE Payment date: 20240129 Year of fee payment: 8 |